Please contact us for more information or to learn if you are eligible to participate.
The primary objective is to compare the progression-free survival (PFS) in patients with newly diagnosed advanced stage classical Hodgkin lymphoma randomized to N-AVD (nivolumab, doxorubicin, vinblastine, dacarbazine) versus that obtained with BV-AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine).
Jose Cruz, MD
National Cancer Institute (NCI)
Type of Trial